Fluidigm (FLDM) Investor Presentation - Slideshow

Financial Highlights - Q4 revenue reached $38.3 million[11] - Q4 product and service margin was 52.7% (GAAP) and 61.8% (Non-GAAP)[11] Market Opportunities and Growth - The total addressable market is estimated to be approximately $7 billion[17] - The total addressable market is projected to grow to approximately $9 billion by 2025[18] - Multiplex Proteomics is estimated to have a CAGR of ~8% from 2020-2025[19] - Next-Gen Sequencing Library Prep is estimated to have a CAGR of ~14% from 2020-2025[19] - Midthroughput Molecular Diagnostics is estimated to have a CAGR of ~9% from 2020-2025[19] - Mass Cytometry market is growing at 10%-plus[25] Market Penetration - Academia and Medical Centers: 19% penetrated today, targeting 30% penetration by 2025[27] - Pharma/Biotech: 8% penetrated today, targeting 30% penetration by 2025[27] - CROs: 1% penetrated today, targeting 10% penetration by 2025[27] - Hospitals/Reference Labs: 0% penetrated today, targeting 5% penetration by 2025[27]